

FIG. 1



FIG. 2



FIG. 3



FIG. 5



FIG. 4



FIG. 6



FIG. 7



FIG. 8



FIG. 9



FIG. 10A



FIG. 10B

DB-X	Total	His+	Retested	Known interacting	"Novel" interacting	False positive
None	$1x10^6$	1	0			
p130	$5x10^5$	19	9	0	5 → 2	
DP1	$2x10^5$	7	7	6 → 2	1 → 1	
pRb	$1x10^6$	20	0			
p35	$1x10^6$	20	8	0	8 → 2	0
CDK3	$1x10^6$	38	16			
CDK3	$1x10^6$	38	16			
DCC1	$3x10^6$	81	23	0		
Z bu	$1x10^6$	81	23			

FIG. 11



FIG. 12

OIPE
AUG 2 0 2002
PATENT & TRADEMARK OFFICE
TC 1600/2900

Appln No.: 10/027,219
Applicant(s): Marc Vidal et al.
REVERSE TWO-HYBRID SYSTEMS



FIG. 13



FIG. 14



FIG. 15



FIG. 20



FIG. 16



FIG. 17



FIG. 18A

In vitro mutagenic PCR reaction



In vivo gap repair



FIG. 18B

OIPE JC102 AUG 20 2002 PATENT & TRADEMARK OFFICE



FIG. 19

MARKED BOX 2

283																301	
Q	I	N	L	K	S	H	S	G	P	I	H	V	L	L	I	K	E2F5
Q	I	H	L	K	S	V	S	G	P	I	E	V	L	L	V	K	E2F4
Q	I	H	L	A	S	T	Q	G	P	I	E	V	Y	L	C	E	E2F3
Q	I	Y	L	K	S	T	Q	G	P	I	E	V	Y	L	C	E	E2F2
Q	I	S	L	K	S	K	Q	G	P	I	D	V	F	L	C	E	E2F1
																	E2F1-20
							P				G						E2F1-30
T																	E2F1-32
																	E2F1-31
T																	E2F1-65
N																	

FIG. 21



FIG. 22



FIG. 23A



Sensitivity

Mutagenesis of X (or Y) partner

SELECTION for Foa Resistance



(Restrictive conditions)

Replica-plating

SELECTION for Ura/His growth



(Permissive conditions)

FIG. 23B



FIG. 24



FIG. 25